FHL2

Across TCGA pan-cancer cohorts, FHL2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FHL2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FHL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FHL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where FHL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.513	0.845	.001	38	view →
CCRCC	DFS	Median	II,III,IV	0.295	0.827	.010	31	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
UCEC	DFS	Quartile	All	0.963	0.763	.025	8	view →
GBM	OS	Quartile	All	0.721	0.860	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FHL2–LSCC (DFS)

Open the LSCC breakdown →